Citations 28

Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017

Journal of Managed Care & Specialty Pharmacy | March 30, 2020 | Volume: 26 | Issue: 4 | Pages: 562-567

10.18553/jmcp.2020.26.4.562 | PMID 32223594

Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock

JAMA | February 10, 2020 | Volume: 323 | Issue: 8 | Pages: 734

10.1001/jama.2020.0254 | PMID 32040163

Medicare Prescription Drug Plan Formulary Restrictions After Postmarket FDA Black Box Warnings

Journal of Managed Care & Specialty Pharmacy | October 30, 2019 | Volume: 25 | Issue: 11 | Pages: 1201-1217

10.18553/jmcp.2019.25.11.1201 | PMID 31663461

Feasibility of Using Real-World Data to Replicate Clinical Trial Evidence

JAMA Network Open | October 9, 2019 | Volume: 2 | Issue: 10 | Pages: e1912869

10.1001/jamanetworkopen.2019.12869 | PMID 31596493

Evolution of Medicare Formulary Coverage Changes for Antithrombotic Therapies After Guideline Updates

Circulation | September 30, 2019 | Volume: 140 | Issue: 14 | Pages: 1227-1230

10.1161/circulationaha.119.040580 | PMID 31567008

Evolution of the American College of Cardiology and American Heart Association Cardiology Clinical Practice Guidelines: A 10‐Year Assessment

Journal of the American Heart Association | September 28, 2019 | Volume: 8 | Issue: 19 | Pages: No page available

10.1161/jaha.119.012065 | PMID 31566106

Background The American College of Cardiology and American Heart Association periodically revise clinical practice guidelines. We evaluated changes in the evidence underlying guidelines published over a 10‐year period. Methods and Results Thirty‐five American College of Cardiology/American Heart Association guidelines were divided into 2 time periods: 2008 to 2012 and 2013 to 2017. Guidelines were categorized into the following topic areas: arrhythmias, prevention, acute and stable ischemia, heart failure, valvular heart disease, and vascular medicine. Changes in recommendations were assessed for each topic area. American College of Cardiology/American Heart Association designated class of recommendation as level I, II , or III (I represented “strongly recommended”) and levels of evidence ( LOE ) as A, C, or C (A represented “highest quality”). The median number of recommendations per each topic area was 281 (198–536, interquartile range) in 2008 to 2012 versus 247 (190–451.3, interquartile range) in 2013 to 2017. The median proportion of class of recommendation I was 49.3% and 44.4% in the 2 time periods, 38.0% and 44.5% for class of recommendation II , and 12.5% and 11.2% for class of recommendation III . Median proportions for LOE A were 15.7% and 14.1%, 41.0% and 52.8% for LOE B, and 46.9% and 32.5% for LOE C. The decrease in the proportion of LOE C was highest in heart failure (24.8%), valvular heart disease (22.3%), and arrhythmia (19.2%). An increase in the proportion of LOE B was observed for these same areas: 31.8%, 23.8%, and 19.2%, respectively. Conclusions There has been a decrease in American College of Cardiology/American Heart Association guidelines recommendations, driven by removal of recommendations based on lower quality of evidence, although there was no corresponding increase in the highest quality of evidence.
Medicare Beneficiary Out-of-Pocket Costs for Generic Cardiovascular Medications Available Through $4 Generic Drug Discount Programs

Annals of Internal Medicine | July 24, 2018 | Volume: 169 | Issue: 11 | Pages: 817-819

10.7326/m18-0965 | PMID 30039170

New and incremental FDA black box warnings from 2008 to 2015

Expert Opinion on Drug Safety | December 7, 2017 | Volume: 17 | Issue: 2 | Pages: 117-123

10.1080/14740338.2018.1415323 | PMID 29215916